Table 1.

Patient characteristics.

	AI (n = 70)	GD (n = 73)
Age in years, median (IQR; range)	55.5 (46–62; 25–70)	54.0 (43–61; 24–70)
Sex (male/female)	39 (56%)/31 (44%)	42 (58%)/31 (42%)
ECOG performance status (0/1)	60 (86%)/10 (14%)	62 (85%)/11 (15%)
Histological subtype
Liposarcoma	21 (30%)	16 (22%)
Myxoid liposarcoma	11 (16%)	7 (10%)
Dedifferentiated liposarcoma	7 (10%)	7 (10%)
Pleomorphic liposarcoma	3 (4%)	2 (3%)
Undifferentiated pleomorphic sarcoma	13 (19%)	22 (30%)
Synovial sarcoma	11 (16%)	9 (12%)
Myxofibrosarcoma	9 (13%)	9 (12%)
Leiomyosarcoma	3 (4%)	7 (10%)
Others	13 (19%)	10 (14%)
Site (extremity/trunk)	62 (89%)/8 (11%)	61 (84%)/12 (16%)
Tumour status (primary/recurrent)	69 (99%)/1 (1%)	70 (96%)/3 (4%)
Lymph node (N0/N1)	68 (97%)/2 (3%)	71 (97%)/2 (3%)
Tumour size in cm, median (IQR; range)	9.0 (6.6–12.6; 5.0–26.5)	10.2 (7.5–12.1; 3.7–32.0)
Histological grade (2/3)	48 (69%)/22 (31%)	37 (51%)/36 (49%)
AJCC Stage (IIB/III/IV)	44 (63%)/24 (34%)/2 (3%)	35 (48%)/36 (49%)/2 (3%)

Data are n (%) unless noted otherwise.

AI Adriamycin plus ifosfamide, GD gemcitabine plus docetaxel, AJCC American Join Committee on Cancer, ECOG Eastern Cooperative Group.